Subtype
Malignant Pharyngeal Neoplasm
CI-CAN-00003219Explore in graph →
411 active trials1 approved drugs2 evidence items
- NCIt
- C7545
Loading cancer entity…
Subtype
CI-CAN-00003219Explore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05172258 | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT05126719 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 238 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04910347 | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 57 | Yonsei UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04920344 | Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy | active not recruiting | Phase 2 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04609280 | Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)(SAVER) | active not recruiting | Phase 2 | 52 | University of Maryland, BaltimoreOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04502407 | Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 40 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06854510 | Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. | active not recruiting | Phase 2 / Phase 3 | 196 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05075980 | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | active not recruiting | Phase 2 | 174 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05787639 | Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) | active not recruiting | Phase 2 | 28 | University of California, San DiegoOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04858269 | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | active not recruiting | Phase 2 | 31 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05813626 | Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 89 | Zhejiang Cancer HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | active not recruiting | Phase 2 / Phase 3 | 384 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT04862650 | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 2 | 46 | Marcelo BonomiOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04925544 | Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | active not recruiting | Phase 2 | 13 | Stanford UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05996523 | Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03097939 | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 113 | National Cancer Centre, SingaporeOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT00494182 | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03224000 | Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04825990 | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer(POINT) | active not recruiting | Phase 2 | 30 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06234748 | Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer(ARTHOUSE) | active not recruiting | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03930498 | Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 68 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05201859 | Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05524168 | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05714657 | Shortened Course Adjuvant Radiotherapy Following TORS | active not recruiting | Phase 2 | 104 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | active not recruiting | Phase 1 / Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03822897 | De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma(EVADER) | active not recruiting | Phase 2 | 103 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05312710 | Safety and Efficacy of APG-157 in Head and Neck Cancer | active not recruiting | Phase 2 | 24 | Aveta Biomics, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03734809 | NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | active not recruiting | Phase 2 | 43 | Chinese University of Hong KongOTHER | 2 | Dec 24, 2025 | clinicaltrials |
| NCT05340270 | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma(NeoTurbo) | active not recruiting | Phase 2 | 150 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03383094 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 2 | 126 | Loren Mell, MDOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06009861 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | active not recruiting | Phase 2 | 110 | Peking University Hospital of StomatologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04517214 | Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 246 | Sun Yat-sen UniversityOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06414577 | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | active not recruiting | Phase 2 | 38 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT03813394 | Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC(2018/00947) | active not recruiting | Phase 1 / Phase 2 | 48 | National University Hospital, SingaporeOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05193617 | Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials